Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NicOx has said it will receive an E1 million payment from Pfizer after the FDA cleared a series of planned clinical trials evaluating an experimental treatment for glaucoma.
Subscribe to our email newsletter
The glaucoma drug, PF-03187207, is the lead development compound generated under the August 2004 collaboration agreement between Pfizer and NicOx, which is focused on the development of nitric oxide-donating prostaglandin F2-alpha analogs for the treatment of glaucoma. Pfizer applied for the clinical trials in February.
Pfizer has initiated the trial of PF-03187207, which is expected to have an increased capacity to reduce high Intraocular Pressure (IOP, pressure within the eye), based on the well-known activities of nitric oxide. The development of abnormally high IOP, due to blockage or malfunction of systems controlling the amount of fluid in the eye, is believed to be one of the principal causes of glaucoma. NicOx said the clinical study will test the safety and tolerability of the compound and may provide a first indication of efficacy.
Including this milestone payment, NicOx will have received E5 million from Pfizer in connection with the agreement and stands to receive an additional E32 million, plus royalties, if the collaboration results in the successful commercial development of a product.